Beihai Gofar Chuanshan Biological Co., Ltd.

Headquartered in Beihai, China, Beihai Gofar Chuanshan Biological Co., Ltd. operates in the Chinese pharmaceutical sector, specializing in the production and distribution of a wide array of medical goods. Its product line features various medicines and medical devices, prominently including proprietary Chinese remedies like pearl eyesight eye drops, gastrointestinal granules, and pearl powder. Furthermore, the company extends its services to encompass molecular medical imaging, dedicated tumor radiotherapy centers, and remote technical support for tumor treatment. Established in 1993, the firm adopted its current name, Beihai Gofar Chuanshan Biological Co., Ltd., in May 2021, having previously been known as Beihai Gofar Marine Biological Industry Co., Ltd.

Beihai Gofar Chuanshan Biological Co., Ltd. trades as 600538.SS on SHH. The company is classified in Basic Materials / Agricultural Inputs and reports in CNY.

The current profile places the business in Agricultural Inputs. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Detailed operating-segment data is not available for this symbol yet.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Beihai Gofar Chuanshan Biological Co., Ltd. can be compared against peers such as Hubei Shuanghuan Science and Technology Stock Co.,Ltd, Zhejiang XinNong Chemical Co.,Ltd., Shandong Sino-Agri United Biotechnology Co.,Ltd., Jiangsu Flag Chemical Industry Co., Ltd., Fanli Digital Technology Co.,Ltd, Dahu Health Industry Co., Ltd..

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $3.06B, beta of 0.11, and return on equity of N/A.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

600538.SS currently shows total debt of N/A and beta of 0.11. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.gofar.com.cn

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.